VCM
HZNP

Virtue Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Virtue Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-9
Closed – – 680
2017
Q4 		$0 Buy
+9
New +$126 ﹤0.01% 530

Other funds holding HZNP

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Virtue Capital Management's HZNP Position: Q1 2018 in Review

Virtue Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2018, closing a stake of 9 shares.

Virtue Capital Management first reported a position in HZNP in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 201 funds tracked by Wall St. Rank hold HZNP as of Q1 2018.

  • Virtue Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2018 after selling out during the quarter.
  • Virtue Capital Management sold 9 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2018.
  • Virtue Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2017 and held it in 1 quarter.
  • Virtue Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $0 in Q4 2017.
  • 201 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2018.

Based on Virtue Capital Management's 13F filing for Q1 2018, filed 15 May 2018.